1.
Chie
n YW: Novel drug delivery systems. In: Chein Oral Drug Delivery Systems. New York, Marcel Dekker: 1992; 1-5: 139-146.
2.
Bara
r FSK: In Essential of
rd
Pharmaceutics, 3 edition. New Delhi, Chand S & Company Ltd. 2003; 550.
3. Tripathi KD: Drug for Cough and Bronchial Asthma. In, Tripathi KD. Essential of Medical Pharmacology, 5th edition. New Delhi, Jaypee Brothers Medical Publisher (P) Ltd. 2004; 196.
4.
India
n Pharmacopoeia. Government of India, New Delhi: Controller of
Publications. 2007; 2: 83-4.
5. Mandal U, Gowda V, Ghosh A, Selvan
5, Solomon S, Pal T. Formulation And Optimization Of Sustained Release Matrix
Tablet Of Metformine HCl 500 Mg Using
Response Surface Methodology. YAKUGAKU ZASSHI. 2007; 127: 1281¬1290.
6. Jain S, Yadav SK, Patil UK.
Preparation and Evaluation of Sustained Release Matrix Tablet of Using Natural Polymers. Research J. Pharm. and Tech. 2008; 1(4): 374-376
7. Wells J. Pharmaceutical Preformulation: The Physical Properties of Drug Substances. In, Aulton M.E (edr). Pharmaceutics the Sciences of Dosage Form Design, 2nd edition. London, Churchill Livingstone. 2002; 133-4.
8. Sinko PJ. Martin's physical pharmacy and pharmaceutical sciences, 5th edition. Lippincott Williams and Wilkins. 2006:
557-8.
9. Fiese EF, Hagen TA. Preformulation. In, Lachman L, Lieberman AH, Kanig LJ (edrs). The Theory and Practice of Industrial Pharmacy, 3rd edition. Mumbai, Varghese Publication House. 1991; 182-4.
10. Banker GS, Anderson NR, Lachman L, Lieberman AH, Kanig LJ (edrs). The Theory and Practice of Industrial Pharmacy, 3rd edition. Mumbai, Varghese
Publication House. 1991; 296- 9.
11.
India
n Pharmacopoeia. Government of India, New Delhi: Controller of Publications. 2007; 1: 183 84.
12. Yeole PG, Galatte UC, Babla BI,
Nakhat PD. Design and Evaluation Of Xanthan Gum-based Sustained Release Matrix Tablet of Diclofenac Sodium.
Indian J Pharm. Sci. 2009; 68; 185-9.13. Chaudhari P, Chaudhari S, Barhate N,
Mistry C and Kolsure P: Design and Evaluation floating tablets of Tizanidine Hydrochloride. Indian J. Pharm. Educ.
Res. 2008; 42: 36-43.
14. Indian Pharmacopoeia. Government of India, New Delhi: Controller of
Publications, 2007; 2: 83-84.
15. Dincer Z, Basan H and Goger NG: Quantitative determination of ambroxol in tablets by derivative UV spectrophotometric method and HPLC. J.
Pharm. and Biomed. Anal. 2003; 31: 867¬872.
16. Basak SC, Reddy J and Mani L: Formulation and Release behaviour of sustained release Ambroxol Hydrochloride HPMC matrix tablet. Indian J. Pharma.
Sci. 2006; 68: 594-8.
17. Nie K, Li X, Chen J. Monitoring Ambroxol Hydrochloride Sustained-Release Tablets Release Nilesh V. Ingle.
Int. J. PharmTech Res.2011, 3(1) 313
b
y Fiber-Optic Drug Dissolution In Situ Test System. J. Dissolution Technologies.
2009: 14-7.
18. Yoshioka S and Stella VJ: Stability of
drug and dosage form. New York, Kluwer academic publishers. 2002; 223-224.
19. Chow SC: Stability Testing for
Dissolution. In, Chow SC (edr). Statistical design and analysis of stability studies, New York, Taylor and Francis. 2007; 4¬10.
20. Schwartz JB: Optimization Techniques in Pharmaceutical Formulation and Processing, In, Banker S and Rhodes CT, (edrs). Modern pharmaceutics, New
York, Marcel Dekker. 1990; 803-23.
21. ICH Harmonised Tripartite Guideline. Stability Testing of New Drug Substances and Products Q1A (R2). Current step 4 version. 2003; 3: 8.
Available Online
Thank you for copying data from http://www.arastirmax.com